Daxor corporation submits dual 510(k)/clia-waiver application to the fda for its advanced next-generation blood volume analyzer

The new bva system is designed to be significantly faster, simpler and give results at the bedside oak ridge, tn, jan. 02, 2024 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, today announces it has submitted its next-generation blood volume analyzer - daxor bva - to the u.s. food and drug administration (fda) via the 510(k)/clia-waiver dual submission pathway. potential clearance is expected during the first half of 2024.
DXR Ratings Summary
DXR Quant Ranking